#𝐂𝐎𝐕𝐀𝐗𝐈𝐍 has been found to effectively neutralize the double mutant strain as well.

Bharat Biotech - COVAXIN® Announcement pic.twitter.com/cKvmFPfKlr

— BharatBiotech (@BharatBiotech) April 24, 2021

Covid-19: Bharat Biotech scales up manufacturing of Covaxin to support vaccination campaigns

Bharat Biotech announced the Covaxin capacity expansion to support vaccination campaigns in India and worldwide amid the surge in COVID-19 cases. Currently, Hyderabad-based Bharat Biotech is producing 4 million doses of Covaxin a month, while Pune-based Serum Institute of India (SII) is producing 60 million doses of Covishield.

Brazilian govt's 20 million dose order is still active: Bharat Biotech

Following the denial of certificate for good manufacturing practices (GMP) by the Brazilian Health Regulatory Agency (Anvisa) to Bharat Biotech's Covaxin (Covid-19 vaccine), the Hyderabad-based vaccine maker said, the requirements pointed out during inspection will be fulfilled, the timelines for fulfilment is under discussion with the Brazil National Regulatory Authority and will be resolved soon.

Bad manufacturing practices not just in Trump's Emergent BioSolutions in Baltimore, but also in Modi's India.

'Sapere aude'